Application of Plakett-Burman Screening Design in Optimization of Process Parameters for Formulation of Canaglifozin Nanosuspension

DOI:

https://doi.org/10.37285/ijpsn.2020.13.6.5

Authors

  • Nisha Patel
  • Hitesh A Patel

Abstract

In this study, we sought to improve the dissolution characteristics of a poorly water-soluble BCS class IV drug canaglifozin, by preparing nanosuspension using media milling method. A Plackett–Burman screening design was employed to screen the significant formulation and process variables. A total of 12 experiment were generated by design expert trial version 12 for screening 5 independent variables namely the amount of stabilizer in mg (X1), stirring time in hr (X2), amt of Zirconium oxide beads in gm (X3), amount of drug in mg (X4) and stirring speed in rpm (X5) while mean particle size in nm (Y1) and drug release in 10 min. were selected as the response variables. All the regression models yielded a good fit with high determination coefficient and F value. The Pareto chart depicted that all the independent variables except the amount of canaglifozin had a significant effect (p<0.001) on the response variables. The mathematical model for mean particle size generated from the regression analysis was given by mean particle size = +636.48889 -1.28267 amt of stabilizer(X1) -4.20417 stirring time (X2) -7.58333 amt of ZrO2 beads(X3) -0.105556 amt of drug(X4) -0.245167 stirring speed(X5) (R2=0.9484, F ratio=22.07, p<0.001). Prepared canaglifozin nanosuspension exemplified a significant improvement (p<0.05) in the release as compared to pure canaglifozin and marketed tablet with the optimum formulation releasing almost 80% drug within first 10min. Optimized nanosuspension showed spherical shape with surface oriented stabilizer molecules and a mean particle diameter of 120.5 nm. There was no change in crystalline nature after formulation and it was found to be chemically stable with high drug content.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Nanosuspension, Plackett–Burman screening design, canaglifozin, media milling, stabilizer, Pareto chart, mean particle size

Downloads

Published

2020-11-16

How to Cite

1.
Patel N, Patel HA. Application of Plakett-Burman Screening Design in Optimization of Process Parameters for Formulation of Canaglifozin Nanosuspension. Scopus Indexed [Internet]. 2020 Nov. 16 [cited 2024 Dec. 26];13(6):5208-16. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/1159

Issue

Section

Research Articles

References

Coelln-Hough J (2013). Canagliflozin Advisory Committee Meeting. Janssen Pharm. Compounds S: Canagliflozin Compound Summary for CID 24812758 (2016).

Dietrich E, Powell J and Taylor JR (2013). Canagliflozin: A novel treatment option for type 2 diabetes. Drug Design, Development and Therapy 7: 1399-08.

European Medicines Agency (2013). Assessment Report Canagliflozin. Committee for Medicinal Products for Human Use. EMA/374133/2013.

European Medicines Agency (2014). Assessment Report Vokanamet. Committee for Medicinal Products for Human Use. EMA/179391/2014.

Haas B, Eckstein N, Pfeifer V, Mayer P and Hass MD (2014). Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin. Nutrition and Diabetes 4(11): 1-8.

Jacobs C, Kayser O and Muller RH (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 196: 161-164.

Kakrana M, Sahooa NG, Lia L, Judeh Z, Wang Y, Chong K and Loh L (2010) Fabrication of drug nano-particles by evaporative precipitation of nanosuspension. Int. J. Pharm. 383: 285-292.

Kayser O, Olbrich C, Yardley V, Kinderlen AF and Croft SL (2003). Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 254: 73-75.

Lamos EM, Younk LM and Davis SN (2013). Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Metabolism & Toxicology 9(6): 763-75.

Liversidge GG and Conzentino P (1995a). In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int J Pharm 20: 79-84.

Liversidge GG and Conzentino P (1995b). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125: 309-313.

Political declaration of the high-level meeting of the general assembly on the prevention and control of non-communicable diseases (2012). Resolution adopted by the General Assembly. United Nations: A/RES/66/2.

Seedher N and Bhatia S (2003). Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS Pharm Sci Tech.4(3): 1-8.

Sesha R: Novel SGLT2 inhibitor dosage forms. WIPO Patent; WO2010/045656A2.

Sharma P, Denny WA and Garg S (2009). Effect of wet milling process on the solid state of indomethacin and simvastatin. Int J Pharm 380: 40-48.

Tahara A, Takasu T, Yokono M, Imamura M and Kurosaki E (2016). Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharma-cokinetics, pharmaco-dynamics, and pharmacologic effects. Journal of Pharmacological Science 130(3): 159-69.

Trotta M, Gallarete M, Pattarino F and Morel S (2001). Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Controlled Release 76: 119-128.

Verma S, Gokhale R and Burgessa DJ (2009). A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 9(380): 216-222.